India, Sept. 1 -- The pharmaceutical and biopharmaceutical manufacturing sector in India is evolving into a more data-driven and intelligent ecosystem, as global regulatory bodies continue to emphasise better process understanding, batch consistency, and supply chain resilience. Digital bioprocessing systems, AI-enabled PATs, and RTRTs now allow for the continuous control of the manufacturing processes and quicker product release. For India's robust base of production of generics, biosimilars, and vaccines, this technology is going to improve efficiency of operations, increase competitiveness, and help with implementation of high-value biomanufacturing initiatives, such as the PLI scheme.

The Shift to Digital Bioprocessing

Digital biopr...